Request Demo

Last update 02 Nov 2026

Paclitaxel

Last update 02 Nov 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

EmPAC, LDE-paclitaxel, NanoPac

+ [78]

Target

Tubulin

Action

inhibitors

Mechanism

Tubulin inhibitors

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders+ [10]

Active Indication

Metastatic HER2-Negative Breast CarcinomaRecurrent HER2-Negative Breast CarcinomaAdvanced gastric carcinoma+ [172]

Inactive Indication

Acidemia, IsovalericAcinar Cell CarcinomaAcute Lymphoblastic Leukemia+ [222]

Originator Organization

National Institutes of Health

Active Organization

National Cancer InstituteToLymph Inc.

NRG Oncology

+ [54]

Inactive Organization

The Gynecologic Oncology GroupHQ Specialty Pharma Corp.

Eli Lilly & Co.

+ [54]

License Organization

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Shenyang Sunshine Pharmaceuticals Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

+ [26]

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1992),

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China)

Structure/Sequence

Molecular FormulaC47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS Registry33069-62-4

2,659

Clinical Trials associated with Paclitaxel

NCT07594548

/ Not yet recruitingPhase 1IIT

A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gastroesophageal junction or esophageal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving futibatinib with paclitaxel and ramucirumab may be safe and tolerable in treating patients with locally advanced or unresectable gastric, gastroesophageal junction or esophageal adenocarcinoma.

Start Date09 Sep 2027

Sponsor / Collaborator

Northwestern University

[+1]

NCT07346196

/ Not yet recruitingPhase 2IIT

A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.

Start Date07 Feb 2027

Sponsor / Collaborator

The University of Chicago

NCT07753824

/ Not yet recruitingPhase 2

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).

Start Date16 Jan 2027

Sponsor / Collaborator

M.D. Anderson International España SA

[+2]

100 Clinical Results associated with Paclitaxel

100 Translational Medicine associated with Paclitaxel

100 Patents (Medical) associated with Paclitaxel

55,354

Literatures (Medical) associated with Paclitaxel

01 Feb 2027·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A leakage-controlled multiscale contextual involution-inception framework for spectral-spatial classification of neonatal hyperspectral images

Article

Author: Ceylan, Murat ; Cihan, Mücahit

Early and reliable assessment of neonatal conditions is important in neonatal intensive care units, where non-invasive imaging approaches may provide complementary information for clinical evaluation. Hyperspectral imaging provides a non-invasive means of capturing spatially resolved spectral information from neonatal tissue; however, its high dimensionality and the limited availability of clinical samples make robust model development challenging. This study proposes the Multiscale Contextual Involution-Inception Network (MC-I²Net), a leakage-controlled framework for neonatal HSI classification. The model combines spatially adaptive involution operators, Inception-based multiscale feature extraction, and contextual feature fusion to learn compact and discriminative spectral-spatial representations. A balanced six-class neonatal hyperspectral imaging dataset containing 240 samples was evaluated, including coarctation of the aorta, intracranial hemorrhage, necrotizing enterocolitis, pneumothorax, respiratory distress syndrome, and healthy control groups. Fixed signal-conditioning operations were applied using predefined processing rules, whereas PCA was treated as a data-adaptive transformation. PCA was fitted exclusively on each training fold, and the learned transformation was subsequently applied to the corresponding held-out test fold. All models were assessed using the same 5-fold cross-validation protocol repeated 10 times. MC-I²Net achieved an overall accuracy of 94.38 ± 4.60% and a Macro-F1 score of 94.35 ± 4.57%, with only small numerical differences in OA relative to MC-3DCNN, ViT-HSI, and Swin-HSI. The model used fewer trainable parameters than MC-3DCNN, ViT-HSI, and Swin-HSI and substantially fewer FLOPs than MC-3DCNN, supporting a favorable performance-complexity profile rather than a large predictive-performance margin. An additional anatomically controlled analysis restricted to PTX and RDS samples acquired from the same thoracic region retained an OA of 95.75 ± 6.49% and a Macro-F1 score of 95.66 ± 6.68%. Sequential nested cross-validation, with PCA dimensionality and involution hyperparameters selected using training data only, yielded a pooled outer out-of-fold OA of 95.00% and a Macro-F1 score of 94.98%. Ablation, sensitivity, calibration, nested-validation, runtime, and saliency analyses provided complementary evidence regarding architectural behavior, robustness, computational characteristics, and preliminary explainability. Overall, these findings support MC-I²Net as a proof-of-concept framework for neonatal HSI classification and provide a methodological basis for future prospective, multicenter, and cross-device evaluation.

01 Feb 2027·BIOMATERIALS

Paving the way for immunotherapy: Simvastatin-primed dual-targeting NPTAC overcomes immune resistance in hepatocellular carcinoma

Article

Author: Chen, Chen ; Yin, Dengke ; Li, Yunlong ; Song, Zhengwei ; Huang, Danni ; Yang, Wenshuo ; Liu, Kang ; Sun, Quanwei ; Yang, Ye ; Shen, Wei ; Niu, Wenjing ; Yu, Qiongliu

Immune checkpoint blockade (ICB)-based regimens, tyrosine kinase inhibitors, and transcatheter arterial chemoembolization (TACE) are major clinical options for unresectable hepatocellular carcinoma (HCC), yet their efficacy remains limited by poor tumor targeting, low response rates, insufficient immune activation, and systemic toxicity. To address these challenges, we establish a "Pave the Way Strategy" combining simvastatin (SIM) with a dual-targeted nanoparticle-mediated targeting chimera (Hs/αPD-L1-NPTAC). Oral SIM acts as a dual-function paving agent, it upregulates hepatic low-density lipoprotein receptor (LDLR) expression to enhance nanoparticle delivery, and depletes tumor cell membrane cholesterol to increase rigidity, boosting dendritic cell phagocytosis and antigen presentation. The LDLR/PD-L1 dual-targeted Hs/αPD-L1-NPTAC enables precise HCC targeting and synchronous intracellular functions. It releases paclitaxel (PTX), promotes intracellular downregulation of PD-L1 and LDLR through endolysosomal trafficking, and cooperates with SIM to establish dual metabolic intervention by simultaneously suppressing cholesterol synthesis and limiting exogenous cholesterol uptake. In immunocompetent orthotopic HCC models, this strategy potently inhibits tumor growth and lung metastasis, prolongs survival, enhances CD8⁺ cytotoxicity T cell, and remodels the immunosuppressive tumor microenvironment. This paradigm provides a promising approach to overcome ICB resistance and enable precision immunotherapy for HCC.

01 Feb 2027·BIOMATERIALS

Natural phenolic acid-based self-assembly promotes anti-tumor immune amplification by ATP-ADO axis regulation and its spiky structure

Article

Author: Zhao, Xiaomin ; Ruan, Xin ; Zhou, Guoliang ; Wang, Xin ; Yue, Zongxin ; Cao, Yuqi ; Deng, Dawei ; Liu, Xinhe ; Hu, Jia

The integration of bioactive micro-nano drug carrier components with rational design of morphological structures is poised to address the therapeutic challenge in anti-tumor immunotherapy focusing on immunogenic cell death (ICD). In this article, based on ATP-adenosine (ADO) axis regulation induced by ellagic acid (EA), the spiky self-assembly (EZ) was tailored with EA and Zn²⁺, and next engineered to construct ATP and pH dual-responsive EZ@MTPP for anti-tumor immune amplification. Following intratumoral injection, the spiky structure of EZ@MTPP enabled efficient local retention, then the ATP-sensitive spines of EZ slowly discharged EA and Zn²⁺ while scavenging ATP. EA silenced the ATP-ADO pathway, lowering immunosuppressive ADO and PD-L1 levels, and Zn²⁺ activated the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) stimulator of interferon genes (STING) signaling pathway cascade and downstream immunity. Concomitantly, acidification of the TME triggered detachment of microwave-induced tumor-derived microparticles loaded with paclitaxel (MTPP) from EZ, which were acquired by neighboring tumor cells to release paclitaxel (PTX) to elicit apoptosis and robust ICD. After coupling the spiky EA-based self-assembly with PTX-loaded MTPP, EZ@MTPP MPs eradicated tumor cells, relieved ADO-mediated immunosuppression and amplified ICD-driven immunity by components and morphological structures co-facilitation, offering an innovative paradigm for metabolism-focused cancer immunotherapy.

1,554

News (Medical) associated with Paclitaxel

29 Oct 2026

·ir.actiniumpharma.com

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

ATNM-400 demonstrated activity across EGFR-, KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established treatments In colorectal cancer, adding ATNM-400 to standard therapy increased tumor growth inhibition to 72% from 25% for oxaliplatin and bevacizumab in a poorly responsive model with moderate target expression In ovarian cancer, ATNM-400 achieved 93% tumor growth inhibition as monotherapy and retained activity following bevacizumab failure Three presentations expand the preclinical foundation for ATNM-400 as a potential pan-tumor treatment, complementing ongoing clinical development in prostate cancer NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results demonstrating the broad antitumor potential of ATNM-400 across non-small cell lung cancer (NSCLC), colorectal cancer and ovarian cancer models. The findings were presented in an oral presentation and two e-posters at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), October 17–21, 2026, in Vienna, Austria. ATNM-400 is the Company's first-in-class Actinium-225 (²²⁵Ac) antibody radioconjugate targeting HER3, a tumor-associated antigen implicated in cancer-cell survival and treatment resistance. By delivering high-energy alpha-particle radiation to HER3-expressing tumor cells, ATNM-400 is designed to induce DNA double-strand breaks through a mechanism distinct from conventional pathway inhibition. The EANM results demonstrate activity across molecularly diverse tumors and treatment-resistant disease, supporting development as both a standalone therapy and a combination partner for established treatments. The studies broaden ATNM-400's preclinical evidence beyond previously reported prostate and breast cancer findings and extend its lung cancer program across multiple oncogenic drivers. Together with the Company's ongoing clinical development in metastatic castration-resistant prostate cancer (mCRPC), these results support a strategy to advance ATNM-400 across multiple large solid tumor indications. Sandesh Seth, Actinium's Chairman and CEO, said, "These results strengthen our conviction in ATNM-400's pan-tumor potential and our opportunity to expand targeted radiotherapy across major solid tumor indications. In lung cancer, activity across EGFR-, KRAS- and ALK-driven models supports an approach that could reach patients beyond a single mutation-defined population. In colorectal cancer, ATNM-400 substantially improved tumor control when added to a standard regimen with limited activity, while in ovarian cancer it demonstrated strong single-agent activity, including after bevacizumab failure. This breadth of activity supports our vision for ATNM-400 as a potential treatment backbone, both on its own and alongside established therapies, for patients whose cancers are inadequately served by current options." Adeela Kamal, Ph.D., Actinium's Chief Scientific Officer, added, "HER3 provides a compelling biological link across these cancers through its role in tumor-cell survival and treatment resistance. ATNM-400 uses this target to deliver the potent DNA-damaging effects of Actinium-225, with activity that is not dependent on inhibiting a specific oncogenic driver. The activity across distinct lung cancer subtypes, improved responses to standard therapy in colorectal cancer, and retained activity after bevacizumab failure in ovarian cancer strengthen the scientific rationale for this approach. These findings support further development of ATNM-400 across HER3-expressing solid tumors, with combinations selected to build on its single-agent activity." Highlights from the EANM 2026 Presentations Non-Small Cell Lung Cancer | Oral Presentation EPS-149 ATNM-400 demonstrated antitumor activity across EGFR-mutant, KRAS G12C-mutant and ALK-rearranged NSCLC models, supporting a HER3-directed approach with potential beyond any single oncogenic driver. In the KRAS G12C-mutant NCI-H358 model, ATNM-400 monotherapy achieved 81% tumor growth inhibition (TGI), compared with 38% for adagrasib and 29% for the HER3-directed antibody-drug conjugate patritumab deruxtecan. Combining ATNM-400 with adagrasib increased TGI to 105%, consistent with tumor regression. These findings support both single-agent activity and the potential to deepen responses to KRAS-targeted therapy. In the ALK-rearranged NCI-H3122 model, ATNM-400 plus crizotinib achieved 97% TGI, compared with 50% for ATNM-400, 55% for crizotinib and 26% for patritumab deruxtecan alone. ATNM-400-containing regimens were well tolerated and extended survival relative to controls and the HER3-directed antibody-drug conjugate. In the EGFR-mutant NCI-H1975 model, ATNM-400 plus pemetrexed and cisplatin achieved 86% TGI, compared with 52% for amivantamab plus chemotherapy and 48% for amivantamab plus lazertinib. ATNM-400 monotherapy achieved 63% TGI. The ATNM-400 and chemotherapy combination also prolonged survival during the study period. Colorectal Cancer | e-Poster EP-0163 ATNM-400 demonstrated combination activity in colorectal cancer models spanning moderate-to-high HER3 expression, including tumors with limited sensitivity to standard therapy. In the HCT15 model with moderate HER3 expression, ATNM-400 plus oxaliplatin and bevacizumab achieved 72% TGI, compared with 25% for oxaliplatin and bevacizumab and 27% for ATNM-400 alone at the corresponding dose. The combination extended survival, supporting its potential to improve tumor control where standard therapy has limited activity. In the SW620 model with high HER3 expression, ATNM-400 plus bevacizumab achieved 88% TGI, comparable to 85% for oxaliplatin plus bevacizumab, while ATNM-400 monotherapy achieved 57% TGI. Survival with ATNM-400 plus bevacizumab was also comparable to the chemotherapy-containing regimen, supporting further evaluation of a combination that omits oxaliplatin. Ovarian Cancer | e-Poster EP-0176 ATNM-400 demonstrated strong single-agent activity in ovarian cancer, including after bevacizumab failure, with additional survival findings in an immunocompetent model of disseminated disease. In the OVCAR-5 model, ATNM-400 monotherapy achieved 93% TGI, compared with 54% for bevacizumab. The combination achieved 85% TGI without additional benefit over ATNM-400 alone, highlighting the strength of its standalone activity in this model. ATNM-400-containing regimens were favorably tolerated and prolonged survival relative to control groups. Following bevacizumab failure, ATNM-400 monotherapy retained activity, achieving 50% TGI with prolonged survival and favorable tolerability. These findings support development in treatment-resistant ovarian cancer. In the disseminated ID8-fLuc ovarian cancer model in immunocompetent mice, ATNM-400-containing regimens prolonged survival relative to their respective controls. Combinations with carboplatin and paclitaxel also prolonged survival compared with chemotherapy alone. Survival follow-up remained ongoing at the time of the presentation, with some animals in ATNM-400 treatment groups still alive. Preclinical Tolerability and Translational Development The studies generally showed favorable tolerability at the evaluated doses. In ovarian cancer studies, single-bolus and fractionated dosing produced minimal changes in assessed blood, liver and kidney markers. No treatment-related abnormalities were observed in the assessed markers in the HCT15 colorectal model; a slight ALT elevation was observed with ATNM-400 plus bevacizumab in the SW620 model. These findings support continued translational evaluation of ATNM-400 as monotherapy and in selected combinations. About ATNM‑400 and HER3 ATNM‑400 is an investigational antibody radioconjugate that pairs the HER3‑targeting monoclonal antibody barecetamab with the alpha‑emitting isotope Actinium‑225. Its antibody‑based design combines antigen‑specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high‑energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ⁸⁹Zr‑labeled imaging counterpart support this development rationale alongside the approximately 10‑day half‑life of ²²⁵Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development. ATNM‑400 is differentiated from PSMA‑targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA‑directed approaches include Novartis' Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals' TLX591‑Tx, Clarity Pharmaceuticals' ⁶⁷Cu‑SAR‑bisPSMA, Convergent Therapeutics' CONV01‑α, AstraZeneca's AZD2265 (formerly FPI‑2265), Curium's lutetium‑177 zadavotide guraxetan (¹⁷⁷Lu‑PSMA‑I&T), ARTBIO's AB001 and AdvanCell's ADVC001. These programs span small‑molecule and antibody‑based therapies using beta‑ or alpha‑emitting isotopes. ATNM‑400 combines HER3 targeting with an Actinium‑225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA‑low or PSMA‑negative disease and those who do not respond to or progress following PSMA‑directed treatment. Its HER3‑directed mechanism also supports investigation beyond prostate cancer in other HER3‑expressing solid tumors. HER3, also known as ERBB3, is a member of the epidermal growth factor receptor family involved in signaling pathways that support tumor growth, survival and resistance to treatment. HER3‑directed antibody‑drug conjugates in clinical development include BioNTech and MediLink's BNT326/YL202, Bristol Myers Squibb and SystImmune's EGFR × HER3 bispecific ADC izalontamab brengitecan (iza‑bren), and Daiichi Sankyo and Merck's patritumab deruxtecan (HER3‑DXd). These programs underscore the clinical development interest in HER3 as an oncology target. ATNM‑400 applies a distinct payload strategy, using alpha radiation in place of a conventional cytotoxic drug. Its preclinical activity in prostate, non‑small cell lung and breast cancer models supports investigation as a potential pan‑cancer radiotherapy, as a monotherapy and in rational combinations. About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology‑driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM‑400 and Actimab‑A with pan‑tumor potential; (2) Actimab‑A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab‑B for bone marrow transplant and Iomab‑ACT for cell and gene therapy conditioning. ATNM‑400 targets HER3, an antigen distinct from PSMA, and is in a first‑in‑human Phase 1 study in mCRPC, with preclinical activity across metastatic castration‑resistant prostate cancer (mCRPC), non‑small cell lung cancer (NSCLC), and breast cancer. Actimab‑A has shown improved survival in relapsed/refractory AML with CLAG‑M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron‑based production of Ac‑225. For more information, please visit www.actiniumpharma.com. Forward‑Looking Statements This press release may contain projections or other "forward‑looking statements" within the meaning of the "safe‑harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10‑K, subsequent quarterly reports on Forms 10‑Q and Forms 8‑K, each as amended and supplemented from time to time. Investors: investorrelations@actiniumpharma.com View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-presents-eanm-2026-results-reinforcing-atnm-400s-pan-tumor-potential-across-lung-colorectal-and-ovarian-cancer-models-302913279.html SOURCE Actinium Pharmaceuticals, Inc. Released October 20, 2026

Clinical ResultRadiation TherapyPhase 1

29 Oct 2026

·www.astrazeneca.com

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys

AstraZeneca advances its ambition to revolutionise cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, 23-27 October 2026. More than 100 abstracts will be presented, including data from five pivotal Phase III trials, four of which will be featured in Presidential Symposia. This breadth of data will demonstrate how AstraZeneca is redefining the way cancer is treated with innovative combinations, precision medicine and antibody drug conjugates (ADCs) across bladder, lung and gastric cancers. Highlights include: CLARITY-Gastric01: Phase III trial of sonesitatug vedotin (Sone-Ve), a wholly owned Claudin-18.2 (CLDN18.2) ADC, in 2nd and later-line CLDN18.2-positive (≥25%) advanced gastric or gastroesophageal junction (GEJ) cancers versus investigator’s choice of therapy. This is the first Phase III trial to show a statistically significant and clinically meaningful overall survival (OS) benefit with an anti-CLDN18.2 ADC in this setting. Approximately 60% of patients have CLDN18.2 expression ≥25% in this setting. (Presidential Symposium 2 Abstract #LBA7). SAFFRON: Phase III trial of Tagrisso (osimertinib) plus Orpathys (savolitinib) in patients with MET-driven, epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who progressed on prior treatment versus platinum-based chemotherapy (Presidential Symposium 2 Abstract #LBA6). DeLLphi-305: Amgen-led Phase III trial of Imfinzi (durvalumab) plus tarlatamab as a 1st-line maintenance treatment for extensive-stage small cell lung cancer versus Imfinzi alone (Presidential Symposium 1 Abstract #LBA3). VOLGA: Phase III trial of perioperative Imfinzi in combination with neoadjuvant enfortumab vedotin in patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy, versus surgery with or without approved adjuvant treatment (Presidential Symposium 1 Abstract #LBA2). SANOVO: Hutchmed-led Phase IIItrial of Tagrisso plus Orpathys in treatment-naïve patients with MET-overexpressed, EGFRm locally advanced or metastatic NSCLC versus Tagrisso alone in China (Proffered Paper Abstract #LBA69). NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase II perioperative trial of Imfinzi combinations with Datroway (datopotomab deruxtecan), oleclumab and monalizumab in NSCLC (Rapid Oral Session Abstract #4244RO). FONTANA: Phase I/IIa trial of torvutatug samrotecan (Torvu-Sam), a folate receptor α (FRα)-targeting ADC as monotherapy in patients with platinum-resistant recurrent ovarian cancer (Rapid Oral Session Abstract #1245RO). AZD7003: Updated results from a Phase I trial of C-CAR031, a Glypican 3 (GPC3) CAR-T, in advanced hepatocellular carcinoma (Rapid Oral Session Abstract #1680RO). Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: "AstraZeneca’s portfolio of scientific data at ESMO is our strongest to date, showcasing transformative combinations including emerging modalities. Findings from VOLGA, DeLLphi-305 and SAFFRON demonstrate the potential of combination regimens with complementary mechanisms to improve on today’s standards of care, extend treatment benefit and meaningfully improve survival outcomes for more patients. These data, alongside practice-changing results for our first wholly owned ADC Sone-Ve from CLARITY-Gastric01 underscore how AstraZeneca is transforming cancer care." Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “At ESMO, we are presenting pivotal data that demonstrate how we are advancing new standards of care by adding novel medicines to AstraZeneca’s proven backbone therapies. Results from VOLGA, DeLLphi-305 and SAFFRON highlight the potential of innovative Imfinzi- and Tagrisso-based regimens to improve outcomes for patients across bladder and lung cancers, reinforcing our commitment to continually raising the bar for patients with cancer across the treatment landscape." Key AstraZeneca presentations during ESMO 20261 Lead Author Abstract Title Presentation details (CEST) Lead Author Antibody drug conjugates Lead Author Xu, R-H Abstract Title CLARITY-Gastric01 (CG-01): a Phase III trial of Sone-Ve in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC) Presentation details (CEST) Abstract #LBA7 Presidential Symposium 2 25 October 2026 4:30 PM Lead Author Meric-Bernstam, F Abstract Title Updated results from FONTANA: Torvutatug samrotecan (torvu-sam), a folate receptor α (FRα)-targeted antibody-drug conjugate (ADC), in patients (pts) with platinum-resistant ovarian cancer (PROC) Presentation details (CEST) Abstract #1245RO Rapid Oral Session 24 October 2026 Lead Author Dent, R Abstract Title First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02 (TB-02) Presentation details (CEST) Abstract #LBA96 Proffered Paper Session 24 October 2026 8:30 AM Lead Author Boileau, JF Abstract Title DESTINY-Breast11 (DB-11): MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose- dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ early breast cancer (eBC) Presentation details (CEST) Abstract #543RO Rapid Oral Session 23 October 2026 4:15 PM Lead Author Novello, S Abstract Title First-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: Patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04) Presentation details (CEST) Abstract #LBA74 Rapid Oral Session 24 October 2026 9:00 AM Lead Author Manich, S Abstract Title A DESTINY-Breast09 (DB-09) analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs) Presentation details (CEST) Abstract #LBA49 Rapid Oral Session 26 October 2026 10:15 AM Lead Author Immuno-oncology Lead Author Powles, T Abstract Title Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial Presentation details (CEST) Abstract #LBA2 Presidential Symposium 1 24 October 2026 4:30 PM Lead Author Sands, J Abstract Title Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial Presentation details (CEST) Abstract #LBA3 Presidential Symposium 1 24 October 2026 4:30 PM Lead Author Kudo, M Abstract Title Liver function trajectory and post-progression outcomes in the Phase III EMERALD-3 trial of tremelimumab (T) + durvalumab (D) ± lenvatinib (L) + transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible hepatocellular carcinoma (eeHCC) Presentation details (CEST) Abstract #LBA48 Proffered Paper Session 24 October 2026 10:15 AM Lead Author Westin, S Abstract Title Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): interim overall survival (OS) and safety from the randomised Phase III DUO-E/GOG-3041/ENGOT-EN10 trial Presentation details (CEST) Abstract #LBA37 Proffered Paper Session 24 October 2026 2:45 PM Lead Author De Santis, M Abstract Title Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POTOMAC Presentation details (CEST) Abstract #4737RO Rapid Oral Session 24 October 2026 10:15 AM Lead Author Cascone, T Abstract Title NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase III perioperative trial Presentation details (CEST) Abstract #4244RO Rapid Oral Session 25 October 2026 8:30 AM Lead Author Spicer, J Abstract Title ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE Presentation details (CEST) Abstract #LBA69 Rapid Oral Session 26 October 2026 10:15 AM Lead Author Lorenza, R Abstract Title Seven-year overall survival (OS) and OS by tumour response measures from the Phase III HIMALAYA trial of tremelimumab plus durvalumab in first-line (1L) unresectable hepatocellular carcinoma (uHCC) Presentation details (CEST) Abstract #1683P Poster Session 25 October 2026 12:00 PM Lead Author Tumour drivers and resistance Lead Author Lu, S Abstract Title Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase III primary results Presentation details (CEST) Abstract #LBA6 Presidential Symposium 2 25 October 2026 4:30 PM Lead Author Wu, YL Abstract Title Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase III SANOVO trial Presentation details (CEST) Abstract #LBA69 Proffered Paper Session 26 October 2026 8:30 AM Lead Author Fizazi, K Abstract Title Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone sensitive prostate cancer (mHSPC): updated overall survival (OS) from CAPItello-281 Presentation details (CEST) Abstract #LBA56 Rapid Oral Session 23 October 2026 1:30 PM Lead Author Cell therapy Lead Author Liang, T Abstract Title Phase I trial of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC): Updated Results Presentation details (CEST) Abstract #1680RO Rapid Oral Session 26 October 2026 2:45 PM 1 More than 100 abstracts at ESMO 2026 will feature AstraZeneca medicines and pipeline molecules Notes AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. Oncology Corporate and financial

Clinical ResultPhase 3Phase 1Phase 2Immunotherapy

29 Oct 2026

·www.biospace.com

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

New data from six landmark trials reinforce practice-changing results of Enhertu and Datroway across a broad spectrum of patients in breast and lung cancer Additional analyses from two trials of raludotatug deruxtecan in ovarian cancer demonstrate emerging potential in gynecological cancers TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 30 abstracts, including four late breaking presentations, in multiple cancers at the 2026 European Society for Medical Oncology (#ESMO26) Congress. New data from six landmark trials demonstrate the company’s progress toward advancing new standards of care for patients in breast and lung cancer, including the DESTINY-Breast05 ( 539RO ), DESTINY-Breast06 ( 4279P ), DESTINY-Breast09 ( LBA49 ), DESTINY-Breast11 ( 543RO ) and DESTINY-Lung04 ( LBA74 ) phase 3 trials of Enhertu ® (trastuzumab deruxtecan) and the TROPION-Breast02 ( LBA96 ) phase 3 trial of Datroway ® (datopotamab deruxtecan). Additional data at ESMO also will spotlight the company’s commitment to advancing research for patients with advanced ovarian cancer across lines of therapy. An updated analysis, including progression-free survival and duration of response, will be presented from the REJOICE-Ovarian01 ( 1331P ) phase 2/3 trial evaluating raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer. A mini oral presentation will highlight preliminary findings from the REJOICE-Ovarian02 ( 1247RO ) phase 1b/2 trial evaluating raludotatug deruxtecan in combination with bevacizumab in patients with platinum-resistant ovarian cancer. “The promising data for raludotatug deruxtecan in ovarian cancer and the robust scientific innovation demonstrated across our pipeline reflects our progress in advancing research for patients across multiple types of cancer,” said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. “Daiichi Sankyo continues to draw from its scientific and technological expertise to turn science into new medicines that can change the standard of care.” Data Demonstrate Benefit of DXd ADCs in Patients with Brain Metastases Research updates highlighting the impact of DXd ADCs in patients with brain metastases include late-breaking rapid oral and proffered paper presentations from the DESTINY-Breast09 ( LBA49 ) phase 3 trial evaluating Enhertu in combination with pertuzumab as a first-line treatment for patients with HER2 positive metastatic breast cancer and the TROPION-Breast02 ( LBA96 ) phase 3 trial evaluating Datroway as a first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option. Final overall survival results of the TUXEDO-3 ( 690O ) phase 2 trial of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases from metastatic breast cancer, advanced non-small cell lung cancer (NSCLC) or leptomeningeal disease from any solid tumor will be presented as a proffered paper. New Data and Trials-in-Progress Presentations Across DXd ADC Portfolio Additional data highlighting new research across the DXd ADC portfolio include oral and poster presentations, including final results of the TALENT ( LBA23 ) phase 2 trial of Enhertu alone or in combination with anastrozole, or in sequence with chemotherapy, as neoadjuvant treatment for patients with HR positive, HER2 low early stage breast cancer. New data in NSCLC include the NeoCOAST-2 ( 4244RO ) phase 2 trial reporting event-free survival results, as well as findings on the association of ctDNA clearance with clinical outcomes in patients with resectable, early stage NSCLC treated with a combination of Datroway plus durvalumab and chemotherapy, and a retrospective analysis evaluating mechanisms of insensitivity to the Datroway payload in subgroups of patients with advanced NSCLC in the TROPION-Lung01 ( 4451P ) phase 3 trial. Updated findings from the EPOC2003 ( 2888P ) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer: results from ESPERANZA ( 1014P ), an external comparator study evaluating Enhertu versus real-world standard of care as a second line or later treatment for patients with HER2 IHC 3+ solid tumors; and, the primary analysis evaluating patritumab deruxtecan monotherapy in patients with melanoma in the HERTHENA-PanTumor01 ( 2073RO ) phase 2 trial also will be presented. Trials-in-progress poster presentations include the DESTINY-Breast Guide ( 1795TiP ) prospective and interventional trial evaluating first-line treatment with Enhertu plus pertuzumab followed by palbociclib, endocrine therapy and dual HER2 blockade (trastuzumab plus pertuzumab), as well as retreatment with Enhertu following progression on maintenance therapy (palbociclib, endocrine therapy and trastuzumab plus pertuzumab) in previously untreated patients with HER2 positive advanced or metastatic breast cancer and the TROY ( 1335TiP ) phase 2 trial evaluating Enhertu in patients with recurrent ovarian cancer with disease progression on prior PARP inhibitor therapy. An overview of late-breaking, clinical data and trials-in-progress presentations from the ADC portfolio of Daiichi Sankyo includes: Presentation Title Author Abstract Presentation (CEST) LBAs Final results of TALENT: a neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer S. Hurvitz LBA23 Proffered Paper Presentation Friday, October 23 1:30 pm – 3:00 pm First-line datopotamab deruxtecan (Dato-DXd) vs. chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: exploratory analysis of patients with brain metastases in TROPION-Breast02 R. Dent LBA96 Proffered Paper Presentation Saturday, October 24 8:30 am – 10:00 am First-line trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant NSCLC: patient-reported outcomes from DESTINY-Lung04 S. Novello LBA74 Rapid Oral Presentation Saturday, October 24 8:30 am – 10:00 am DESTINY-Breast09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab for patients with HER2+ advanced/metastatic breast cancer and baseline brain metastases C. Saura LBA49 Rapid Oral Presentation Monday, October 26 10:15 am – 11:45 am Breast DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab vs. dose-dense doxorubicin + cyclophosphamide followed by THP in HER2+ early breast cancer J.F. Boileau 543RO Rapid Oral Presentation Friday, October 23 4:15 pm – 5:45 pm Patient-reported outcomes from DESTINY-Breast05: health-related quality of life with trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2 positive early breast cancer C. Barrios 539RO Rapid Oral Presentation Friday, October 23 4:15 pm – 5:45 pm Paired-biopsy multi-omic analysis reveals target-independent mechanisms of antibody-drug conjugate resistance in metastatic breast cancer P. Tarantino 4449RO Rapid Oral Presentation Monday, October 26 10:15 am – 11:45 am Trastuzumab deruxtecan (T-DXd) vs. physician’s choice of chemotherapy in HR+, HER2 low metastatic breast cancer: a DESTINY-Breast06 ctDNA molecular response analysis G. Curigliano 4279P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm Trastuzumab deruxtecan (T-DXd) + pembrolizumab in previously treated human epidermal growth factor receptor 2-expressing advanced or metastatic breast cancer: primary analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106 H. Rugo 1771P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm DESTINY-Breast Respond HER2 low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2 low metastatic breast cancer: update on baseline characteristics and anti-emetic treatment J.Y. Pierga 12P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Improving accuracy in HER2 ultralow identification: multi-site validation of an AI-decision support tool B. Van der Vegt 1784P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Comparative evaluation of 7 artificial intelligence tools for HER2-low and ultralow scoring in breast cancer J.S. Frenel 287P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)-based therapy followed by palbociclib, endocrine therapy, and dual HER2 blockade in first-line human epidermal growth factor receptor positive, hormone receptor-positive advanced or metastatic breast cancer and retreatment with T-DXd (DESTINY-Breast Guide) S. Sammons 1795TiP Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Lung NeoCOAST-2: association of ctDNA clearance with clinical outcomes in a global platform phase 2 perioperative trial T. Cascone 4244RO Rapid Oral Presentation Sunday, October 25 8:30 am – 10:00 am Mechanisms of insensitivity to the datopotamab deruxtecan (Dato-DXd) payload in subgroups of patients with advanced non-small cell lung cancer in TROPION Lung01 N. Girard 4451P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: IDeate-Lung01 updated results M. Ahn 3842P Poster Presentation Monday, October 26 12:00 pm – 12:45 pm Ovarian Raludotatug deruxtecan (R-DXd) + bevacizumab in participants with platinum-resistant recurrent ovarian cancer: results for cohort B-1 of the phase 1b/2 REJOICE-Ovarian02 study A. Oaknin 1247RO Rapid Oral Presentation Saturday, October 24 08:30 am – 10:00 am Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: an updated analysis of efficacy and tolerability from the phase 2 part of REJOICE-Ovarian01 K. Hasegawa 1331P Poster Presentation Monday, October 26 12:00 pm – 12:45 pm A randomized phase 2, open-label, multicenter, study of trastuzumab deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14) J.Y. Lee 1335TiP Poster Presentation Monday, October 26 12:00 pm – 12:45 pm Gastric Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma from DESTINY-Gastric04 M. Gumus 2925P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm Perioperative trastuzumab deruxtecan plus capecitabine and durvalumab in HER2 positive gastric or gastroesophageal junction cancer: a phase II study (EPOC2003) D. Takahari 2888P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm PanTumor Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases and leptomeningeal disease M. Preusser 690O Proffered Paper Presentation Sunday, October 25 10:15 am – 11:45 am Patritumab deruxtecan (HER3-DXd) in melanoma after anti-PD-(L)1 therapy: primary analysis from HERTHENA-PanTumor01 M. McKean 2073RO Rapid Oral Presentation Sunday, October 25 10:15 am – 11:45 am ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors F. Meric-Bernstam 1014P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of nine ADCs in clinical development crafted from ADC technology discovered in-house by Daiichi Sankyo. The DXd ADC Technology platform of Daiichi Sankyo consists of seven ADCs in clinical development where each ADC is comprised of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADCs include Enhertu and Datroway, which are being jointly developed and commercialized globally with AstraZeneca, and ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd) and patritumab deruxtecan (HER3-DXd), which are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939 and DS3790 are being developed by Daiichi Sankyo. Additional ADCs being developed by Daiichi Sankyo include DS3610, which consists of an antibody attached to a novel payload that acts as an agonist of STING, and DS1025, which consists of a CD25 directed antibody attached to an immuno-oncology optimized cytotoxic payload. Ifinatamab deruxtecan, raludotatug deruxtecan, patritumab deruxtecan, DS-3939, DS3610, DS3790 and DS1025 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established. About Daiichi Sankyo Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit . Contacts MEDIA CONTACTS: Global: Jennifer Brennan Jennifer.brennan@daiichisankyo.com +1 908 900 3183 (mobile) Japan: DS-PR_jp@daiichisankyo.com INVESTOR RELATIONS CONTACT: DaiichiSankyoIR_jp@daiichisankyo.com

Phase 2Phase 3Clinical ResultADCImmunotherapy

100 Deals associated with Paclitaxel

External Link

KEGG	Wiki	ATC	Drug Bank
D00491	Paclitaxel	L01CD01	DB01229

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic HER2-Negative Breast Carcinoma	China	DAE HWA PHARM Co., Ltd.	29 Sep 2026
Recurrent HER2-Negative Breast Carcinoma	China	DAE HWA PHARM Co., Ltd.	29 Sep 2026
Advanced gastric carcinoma	China	DAE HWA PHARM Co., Ltd.	19 Sep 2024
Advanced gastric carcinoma	China	Haihe Biopharma Co., Ltd.	19 Sep 2024
Pancreatic adenocarcinoma metastatic	European Union	Accord Healthcare SL	05 Jan 2024
Pancreatic adenocarcinoma metastatic	Iceland	Accord Healthcare SL	05 Jan 2024
Pancreatic adenocarcinoma metastatic	Liechtenstein	Accord Healthcare SL	05 Jan 2024
Pancreatic adenocarcinoma metastatic	Norway	Accord Healthcare SL	05 Jan 2024
Platinum-Resistant Primary Peritoneal Carcinoma	European Union	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	Iceland	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	Liechtenstein	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	Norway	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	European Union	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	Iceland	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	Liechtenstein	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	Norway	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	European Union	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	Iceland	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	Liechtenstein	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	Norway	Inceptua SA	20 Nov 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	NDA/BLA	European Union	Accord Healthcare SL	09 Nov 2023
Metastatic Pancreatic Cancer	Phase 3	China	Shanghai Yizhong Pharmaceutical Co., Ltd.	21 Jan 2025
High grade glioma	Phase 3	China	Zhejiang University	01 Apr 2024
Human epidermal growth factor 2 negative carcinoma of breast	Phase 3	China	Shanghai Yizhong Pharmaceutical Co., Ltd.	25 Sep 2023
Cutaneous Squamous Cell Carcinoma	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Hypopharyngeal Carcinoma	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous cell carcinoma of head and neck metastatic	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous cell carcinoma of the hypopharynx	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous Cell Carcinoma of the Larynx	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous cell carcinoma of the oral cavity	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05002127 (ASPEN-06, Pubmed \| Nat Med)	Phase 2/3	HER2-positive gastric cancer HER2-positive	127	Evorpacept plus Trastuzumab, Ramucirumab, and Paclitaxel	legcvfdlsj(ccoyeydevj) = renktqtnkf ydxpqegbum (wglyfhduzk ) View more	Positive	24 Sep 2026
NCT05002127 (ASPEN-06, Pubmed \| Nat Med)	Phase 2/3	HER2-positive gastric cancer HER2-positive	127	Trastuzumab, Ramucirumab, and Paclitaxel	legcvfdlsj(ccoyeydevj) = cofdjuzpsc ydxpqegbum (wglyfhduzk ) View more	Positive	24 Sep 2026
CSCO2026	Not Applicable	Nonseminomatous Germ Cell Tumor	64	High Dose Chemotherapy (HDCT) + Peripheral Blood Stem Cell Transplantation (PBSCT)	uzzonihhxc(njtoelnajh) = wswbtcubug pokoxqppls (gbeuqjxgoo ) View more	Positive	11 Sep 2026
NCT02905591 (XACT-LUNG, CTgov)	Phase 2	Non-Small Cell Lung Cancer	43	Radiation therapy+Ascorbic Acid+Carboplatin+Paclitaxel	xfrfvxlkzf = orowpynchj yslabobuzq (dpbafaixdc, bsuoeagwel - yqzhsuixuv) View more	-	31 Jul 2026
NCT04776447 (APOLLO \| APOLO, CTgov)	Phase 2	Resectable Lung Non-Small Cell Carcinoma \| Non-small cell lung cancer stage IIIA \| Bronchogenic Carcinoma ... View more	38	Carboplatin+Placlitaxel+Atezolizumab	hzvgoyaqkt = fxkjjpvwie irvezlyike (ongzetjjal, ooyfmhtfqi - gfudkvqypf) View more	-	22 Jul 2026
NCT04527900 (CTgov)	Phase 2	Advanced Endometrial Carcinoma	2	pelvic IMPT (Intensity Modulated Proton Therapy)+carboplatin+paclitaxel	lhqiqiczgf = ypcqwqzdgj edcinlvzjs (dthxgulhos, thhbrufqmn - xpxbwtdaqp) View more	-	08 Jul 2026
NCT05519241 (Pubmed \| Nanomedicine (Lond))	Phase 1	Non-Muscle Invasive Bladder Neoplasms	3	PLZ4-coated paclitaxel-loaded micelles (PPM)	ycphedxhel(nsuvydmtju) = No drug-related adverse event was observed apncqszeai (sqeyrntcfl )	Positive	03 Jul 2026
NCT04929392 (CTgov)	Phase 2	Adenocarcinoma of Esophagus \| Gastrooesophageal junction cancer \| Esophageal Squamous Cell Carcinoma ... View more	3	External Beam Radiation Therapy+Carboplatin+Paclitaxel+Pembrolizumab+Lenvatinib Mesylate	aygyuxbfkr = hmtridshaj byrjtwcnuw (jfeihrwruz, shudbyqcpl - tqujtdqjww) View more	-	23 Jun 2026
NCT07001748 (STOPGAP II, ASCO2026)	Phase 2/3	Gastric Neuroendocrine Tumor Second line microsatellite stable	148	Intraperitoneal paclitaxel + Systemic treatment	jdvmejrklm(otfxqoauwm) = dggkfvwwbg rhiynguzfe (oyyheavfmx )	Positive	29 May 2026
NCT07001748 (STOPGAP II, ASCO2026)	Phase 2/3		148	Systemic treatment	vgairehsmu(pxmtrnuqkw) = avvdvfyyct endscnmfij (dcncyczqkj ) View more	Positive	29 May 2026
K-TAIL-201 (ASCO2026)	Phase 2	Non-squamous non-small cell lung cancer First line	32	Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel	jsaloropsz(gawjiksizd) = jtyavfalun jcplqgrcqo (tbetwrdjaq, 40.6 - 76.3) View more	Positive	29 May 2026
NCT06332092 (FID-007-003, ASCO2026)	Phase 2	Squamous Cell Carcinoma of Head and Neck	45	FID-007 75 mg/m2	vgyqqanzhk(lqfznpafob) = rxatsmoqsa kwyqovaebk (atehviiheg ) View more	Positive	29 May 2026
NCT06332092 (FID-007-003, ASCO2026)	Phase 2	Squamous Cell Carcinoma of Head and Neck	45	FID-007 125 mg/m2	vgyqqanzhk(lqfznpafob) = oqarefxhrq kwyqovaebk (atehviiheg ) View more	Positive	29 May 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis